Felix Blanc-Durand,Miriam Koopman,Sandip Pravin Patel et al.
Felix Blanc-Durand et al.
Standardizing Time-to-Event Reporting in Single-Arm BCG-Unresponsive Registration Trials: A Case for Kaplan-Meier [0.03%]
单臂卡介苗无反应登记试验中报告事件发生时间标准化的必要性：Kaplan-Meier方法的优势分析
S M Monda,J J Meeks,T Powles et al.
S M Monda et al.
Sacituzumab Tirumotecan in Participants With Advanced or Metastatic Urothelial Carcinoma and Disease Progression after Chemotherapy and Immune Checkpoint Inhibitors [0.03%]
在接受过化疗和免疫检查点抑制剂治疗后病情进展的晚期或转移性尿路上皮癌受试者中使用sacituzumab govitecan治療
Y Zhu,S Jiang,Y Shi et al.
Y Zhu et al.
Background: Trophoblast cell-surface antigen 2 (TROP2) is overexpressed in advanced or metastatic urothelial cancer (UC), representing a promising therapeutic target. Sacituzumab tirumotecan (sac-TMT) is a TROP2-directed ...
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02 [0.03%]
治疗HER2阳性局部晚期或转移性乳腺癌患者的Tukysa(Tucatinib)与泰素帝(Treasta-Zymene): HER2CLIMB-02随机III期试验的主要分析结果
S A Hurvitz,S Loi,J O&#x;Shaughnessy et al.
S A Hurvitz et al.
Background: Trastuzumab emtansine (T-DM1) is a standard treatment option in patients with previously treated human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metastatic breast cancer (LA/MBC)....
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer [0.03%]
转移性乳腺癌中ESR1突变检测的动力学和决定因素
L Cabel,F Berger,T Bachelot et al.
L Cabel et al.
Background: PADA-1 was the first prospective randomized trial to show that early therapeutic targeting of bESR1mut mutations with fulvestrant provides significant clinical benefit in patients with ER+/HER2- advanced breas...
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03 [0.03%]
T-DXd最佳确认疗效与相关生物标志物在DESTINY-Breast01、DESTINY-Breast02和DESTINY-Breast03研究中的HER2阳性转移性乳腺癌患者中的汇总分析
C Saura,J Cortés,S Modi et al.
C Saura et al.
Background: Objective response rates in the DESTINY-Breast01/02/03 trials, which evaluated trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC), were 62...
ESMO Basic Requirements for AI-based Biomarkers In Oncology (EBAI) [0.03%]
基于人工智能的肿瘤生物标志物的基本要求（EBAI）
M Aldea,M Salto-Tellez,A Marra et al.
M Aldea et al.
Background: Artificial intelligence (AI) is expected to introduce an increasing number of biomarkers in oncology. To bridge the gap between oncology and computer science, it is timely to define recommendations for AI-base...
ASSOCIATION BETWEEN TYPE AND LOCATION OF GERMLINE BRCA1/2 PATHOGENIC OR LIKELY PATHOGENIC VARIANTS WITH PHENOTYPE AND PROGNOSIS IN YOUNG PATIENTS WITH BREAST CANCER: RESULTS FROM AN INTERNATIONAL COHORT STUDY [0.03%]
BRCA1/2胚系致病性或可能致病性变异的类型和位置与乳腺癌年轻患者表型及预后的关联：一项国际队列研究的结果
A Toss,E Blondeaux,E Tenedini et al.
A Toss et al.
Background: Clinical implications of specific pathogenic and likely pathogenic variant (LP/PV) types and locations in the BRCA1 or BRCA2 tumor-suppressor genes remain to be elucidated. ...
Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial [0.03%]
低危弥漫性大B细胞淋巴瘤患者早期正电子发射断层扫描反应适应治疗：一项开放性、多中心、随机、非劣效性三期试验
Jean-Marie Michot,Serge Bologna,Jean-Noël Bastie et al.
Jean-Marie Michot et al.
Background: Preliminary reports suggest interim positron emission tomography (PET) could drive treatment duration in limited-stage diffuse large B-cell lymphoma (DLBCL). This phase 3 randomised study in front-line therapy...